Skip to content
2000
Volume 8, Issue 4
  • ISSN: 1570-162X
  • E-ISSN: 1873-4251

Abstract

HIV-1 has resulted in a devastating AIDS pandemic. An effective HIV/AIDS vaccine that can be used to either, prevent HIV infection, control infection or prevent progression of the disease to AIDS is needed. In this review we discuss the use of Mycobacterium bovis BCG, the tuberculosis vaccine, as a vaccine vector for an HIV vaccine. Numerous features make BCG an attractive vehicle to deliver HIV antigens. It has a good safety profile, elicits long-lasting cellular immune responses and in addition manufacturing costs are affordable, a necessary consideration for developing countries. In this review we discuss the numerous factors that influence generation of a genetically stable recombinant BCG vaccine for HIV.

Loading

Article metrics loading...

/content/journals/chr/10.2174/157016210791208686
2010-06-01
2025-10-14
Loading full text...

Full text loading...

/content/journals/chr/10.2174/157016210791208686
Loading

  • Article Type:
    Research Article
Keyword(s): HIV; Mycobacterium bovis BCG; Recombinant BCG; vaccine vector
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test